Which has better valuation and earnings, KMDA or QURE?

Kamada has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.28 $20.20M $0.35 20.40 uniQure $16.10M 191.36 -$198.97M -$3.48 N/A

Is KMDA or QURE more profitable?

Kamada has a net margin of 11.21% compared to uniQure's net margin of -1,154.42%. Kamada's return on equity of 7.73% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.21% 7.73% 5.41% uniQure -1,154.42% -145.81% -27.15%

Does the media prefer KMDA or QURE?

In the previous week, uniQure had 36 more articles in the media than Kamada. MarketBeat recorded 37 mentions for uniQure and 1 mentions for Kamada. uniQure's average media sentiment score of 0.50 beat Kamada's score of 0.00 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 11 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, KMDA or TYRA?

Kamada has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.28 $20.20M $0.35 20.40 Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A

Is KMDA or TYRA more profitable?

Kamada has a net margin of 11.21% compared to Tyra Biosciences' net margin of 0.00%. Kamada's return on equity of 7.73% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.21% 7.73% 5.41% Tyra Biosciences N/A -42.66% -39.79%

Does the media prefer KMDA or TYRA?

In the previous week, Tyra Biosciences had 2 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Tyra Biosciences and 1 mentions for Kamada. Tyra Biosciences' average media sentiment score of 0.53 beat Kamada's score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KMDA or RXRX?

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Kamada. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 1 mentions for Kamada. Recursion Pharmaceuticals' average media sentiment score of 0.65 beat Kamada's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, GENB or KMDA?

Kamada has higher revenue and earnings than Generate Biomedicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Generate Biomedicines $30.30M 68.67 N/A N/A N/A Kamada $180.46M 2.28 $20.20M $0.35 20.40

Does the media refer more to GENB or KMDA?

In the previous week, Generate Biomedicines had 1 more articles in the media than Kamada. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for Kamada. Generate Biomedicines' average media sentiment score of 0.00 equaled Kamada'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, PGEN or KMDA?

Kamada has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 198.88 -$250.64M -$1.18 N/A Kamada $180.46M 2.28 $20.20M $0.35 20.40

Is PGEN or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Kamada's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -646.99% 717.50% 58.48% Kamada 11.21% 7.73% 5.41%

Does the media prefer PGEN or KMDA?

In the previous week, Precigen had 2 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Precigen and 1 mentions for Kamada. Precigen's average media sentiment score of 0.78 beat Kamada's score of 0.00 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kamada (KMDA) Competitors

$7.14 +0.01 (+0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$7.14 +0.00 (+0.07%)

As of 04:10 PM Eastern

Compare

KMDA vs. QURE, TYRA, RXRX, GENB, and PGEN

Should you buy Kamada stock or one of its competitors? MarketBeat compares Kamada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kamada include uniQure (QURE), Tyra Biosciences (TYRA), Recursion Pharmaceuticals (RXRX), Generate Biomedicines (GENB), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.

How does Kamada compare to uniQure?

Kamada (NASDAQ:KMDA) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Kamada has a net margin of 11.21% compared to uniQure's net margin of -1,154.42%. Kamada's return on equity of 7.73% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
uniQure	-1,154.42%	-145.81%	-27.15%

20.4% of Kamada shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, uniQure had 36 more articles in the media than Kamada. MarketBeat recorded 37 mentions for uniQure and 1 mentions for Kamada. uniQure's average media sentiment score of 0.50 beat Kamada's score of 0.00 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	11 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Kamada presently has a consensus target price of $12.00, suggesting a potential upside of 68.07%. uniQure has a consensus target price of $58.92, suggesting a potential upside of 20.61%. Given Kamada's stronger consensus rating and higher possible upside, equities analysts plainly believe Kamada is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Kamada has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.28	$20.20M	$0.35	20.40
uniQure	$16.10M	191.36	-$198.97M	-$3.48	N/A

Summary

Kamada beats uniQure on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Tyra Biosciences?

Kamada (NASDAQ:KMDA) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Kamada has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.28	$20.20M	$0.35	20.40
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

20.4% of Kamada shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kamada has a net margin of 11.21% compared to Tyra Biosciences' net margin of 0.00%. Kamada's return on equity of 7.73% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Tyra Biosciences	N/A	-42.66%	-39.79%

Kamada has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

In the previous week, Tyra Biosciences had 2 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Tyra Biosciences and 1 mentions for Kamada. Tyra Biosciences' average media sentiment score of 0.53 beat Kamada's score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada presently has a consensus target price of $12.00, suggesting a potential upside of 68.07%. Tyra Biosciences has a consensus target price of $47.00, suggesting a potential upside of 54.76%. Given Kamada's stronger consensus rating and higher possible upside, equities analysts plainly believe Kamada is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Summary

Kamada beats Tyra Biosciences on 11 of the 16 factors compared between the two stocks.

How does Kamada compare to Recursion Pharmaceuticals?

Kamada (NASDAQ:KMDA) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Kamada has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.28	$20.20M	$0.35	20.40
Recursion Pharmaceuticals	$74.68M	22.92	-$644.76M	-$1.20	N/A

20.4% of Kamada shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kamada has a net margin of 11.21% compared to Recursion Pharmaceuticals' net margin of -842.95%. Kamada's return on equity of 7.73% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Kamada has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Kamada. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 1 mentions for Kamada. Recursion Pharmaceuticals' average media sentiment score of 0.65 beat Kamada's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada currently has a consensus target price of $12.00, suggesting a potential upside of 68.07%. Recursion Pharmaceuticals has a consensus target price of $8.10, suggesting a potential upside of 150.77%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Kamada beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Kamada compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Kamada (NASDAQ:KMDA) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

20.4% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Generate Biomedicines had 1 more articles in the media than Kamada. MarketBeat recorded 2 mentions for Generate Biomedicines and 1 mentions for Kamada. Generate Biomedicines' average media sentiment score of 0.00 equaled Kamada'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada has a net margin of 11.21% compared to Generate Biomedicines' net margin of 0.00%. Kamada's return on equity of 7.73% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Kamada	11.21%	7.73%	5.41%

Kamada has higher revenue and earnings than Generate Biomedicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	68.67	N/A	N/A	N/A
Kamada	$180.46M	2.28	$20.20M	$0.35	20.40

Generate Biomedicines presently has a consensus target price of $25.40, suggesting a potential upside of 56.50%. Kamada has a consensus target price of $12.00, suggesting a potential upside of 68.07%. Given Kamada's stronger consensus rating and higher possible upside, analysts plainly believe Kamada is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats Generate Biomedicines on 8 of the 11 factors compared between the two stocks.

How does Kamada compare to Precigen?

Precigen (NASDAQ:PGEN) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Precigen had 2 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Precigen and 1 mentions for Kamada. Precigen's average media sentiment score of 0.78 beat Kamada's score of 0.00 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada has a net margin of 11.21% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Kamada's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Kamada	11.21%	7.73%	5.41%

Precigen presently has a consensus price target of $12.50, suggesting a potential upside of 131.48%. Kamada has a consensus price target of $12.00, suggesting a potential upside of 68.07%. Given Precigen's higher possible upside, research analysts clearly believe Precigen is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

33.5% of Precigen shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kamada has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	198.88	-$250.64M	-$1.18	N/A
Kamada	$180.46M	2.28	$20.20M	$0.35	20.40

Precigen has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Kamada has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Summary

Precigen beats Kamada on 9 of the 15 factors compared between the two stocks.

Get Kamada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KMDA vs. The Competition

Export

Metric	Kamada	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$410.01M	$3.49B	$6.74B	$12.32B
Dividend Yield	2.63%	2.28%	2.68%	5.88%
P/E Ratio	20.40	20.50	25.39	23.96
Price / Sales	2.28	328.65	530.17	107.90
Price / Cash	11.68	130.96	45.29	53.76
Price / Book	1.53	8.26	10.76	6.41
Net Income	$20.20M	$23.91M	$3.56B	$337.14M
7 Day Performance	-1.65%	3.05%	1.37%	-0.48%
1 Month Performance	-8.81%	2.40%	0.81%	0.49%
1 Year Performance	-10.19%	56.35%	30.53%	28.16%

Kamada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KMDA Kamada	4.9158 of 5 stars	$7.14 +0.1%	$12.00 +68.1%	-1.8%	$410.01M	$180.46M	20.40	360	Positive News
QURE uniQure	2.9301 of 5 stars	$27.06 -2.9%	$42.83 +58.3%	+251.5%	$1.71B	$16.10M	N/A	500	Trending News Insider Trade
TYRA Tyra Biosciences	2.5526 of 5 stars	$28.06 -1.7%	$46.00 +63.9%	+209.6%	$1.69B	N/A	N/A	20
RXRX Recursion Pharmaceuticals	3.3403 of 5 stars	$3.17 -3.8%	$8.10 +155.9%	-34.4%	$1.69B	$74.68M	N/A	400
GENB Generate Biomedicines	N/A	$13.19 -2.9%	$25.40 +92.6%	N/A	$1.68B	$30.30M	N/A	312

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KMDA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kamada (KMDA) Competitors

KMDA vs. QURE, TYRA, RXRX, GENB, and PGEN

How does Kamada compare to uniQure?

Summary

How does Kamada compare to Tyra Biosciences?

Summary

How does Kamada compare to Recursion Pharmaceuticals?

Summary

How does Kamada compare to Generate Biomedicines?

Summary

How does Kamada compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kamada (KMDA) Competitors

KMDA vs. QURE, TYRA, RXRX, GENB, and PGEN

How does Kamada compare to uniQure?

Is KMDA or QURE more profitable?

Do institutionals & insiders hold more shares of KMDA or QURE?

Does the media prefer KMDA or QURE?

Which has more volatility & risk, KMDA or QURE?

Do analysts recommend KMDA or QURE?

Which has better valuation and earnings, KMDA or QURE?

Summary

How does Kamada compare to Tyra Biosciences?

Which has better valuation and earnings, KMDA or TYRA?

Do institutionals & insiders hold more shares of KMDA or TYRA?

Is KMDA or TYRA more profitable?

Which has more volatility & risk, KMDA or TYRA?

Does the media prefer KMDA or TYRA?

Do analysts recommend KMDA or TYRA?

Summary

How does Kamada compare to Recursion Pharmaceuticals?

Which has better earnings and valuation, KMDA or RXRX?

Do institutionals and insiders hold more shares of KMDA or RXRX?

Is KMDA or RXRX more profitable?

Which has more volatility & risk, KMDA or RXRX?

Does the media refer more to KMDA or RXRX?

Do analysts prefer KMDA or RXRX?

Summary

How does Kamada compare to Generate Biomedicines?

Do insiders & institutionals hold more shares of GENB or KMDA?

Does the media refer more to GENB or KMDA?

Is GENB or KMDA more profitable?

Which has stronger valuation and earnings, GENB or KMDA?

Do analysts recommend GENB or KMDA?

Summary

How does Kamada compare to Precigen?

Does the media prefer PGEN or KMDA?

Is PGEN or KMDA more profitable?

Do analysts rate PGEN or KMDA?

Do institutionals and insiders hold more shares of PGEN or KMDA?

Which has better valuation & earnings, PGEN or KMDA?

Which has more volatility & risk, PGEN or KMDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA vs. The Competition

Kamada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools